CY1114186T1 - Παραγωγα ιμιδαζολιου ως ανταγωνιστες mglur5 - Google Patents
Παραγωγα ιμιδαζολιου ως ανταγωνιστες mglur5Info
- Publication number
- CY1114186T1 CY1114186T1 CY20131100614T CY131100614T CY1114186T1 CY 1114186 T1 CY1114186 T1 CY 1114186T1 CY 20131100614 T CY20131100614 T CY 20131100614T CY 131100614 T CY131100614 T CY 131100614T CY 1114186 T1 CY1114186 T1 CY 1114186T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lower alkyl
- alkyl
- mglur5
- iib
- imidazoli
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με παράγωγα ιμιδαζολίου του γενικού τύπου I, όπου το R1 σημαίνει αλογόνο, κατώτερο αλκύλιο ή κατώτερο αλκοξύλιο· το R2 σημαίνει κατώτερο αλκύλιο, κατώτερο υδροξυαλκύλιο ή κατώτερο αλκοξυαλκύλιο· το R3 σημαίνει υδρογόνο, κατώτερο αλκύλιο, κατώτερο υδροξυαλκύλιο ή αλκοξυαλκύλιο· το Q σημαίνει είτε -Ν= ή -CH=· το R4 είναι μια ομάδα του τύπου IIα ή IIb(τύπος IIα και ΙΙb) όπου τα Χ, Υ και Ζ είναι ανεξαρτήτως -CH- ή -Ν= και όπου μόνο ένα από τα Χ ή Υ μπορεί να είναι άτομο αζώτου· τα R5 και R6 είναι ανεξαρτήτως υδρογόνο, κατώτερο αλκύλιο, κατώτερο υδροξυαλκύλιο, κατώτερο αλκοξυαλκύλιο, -(CH2)m-(CΟ)O- κατώτερο αλκύλιο, -(CΗ2)m-S(Ο)2-κατώτερο αλκύλιο, -(CΗ2)m-C(Ο)-ΝR’R’’ και όπου το m = 0-3 και τα R’ και R’’ είναι ανεξαρτήτως υδρογόνο ή κατώτερο αλκύλιο· καθώς και με φαρμακευτικώς αποδεκτά άλατα αυτών. Σήμερα εντελώς αναπάντεχα βρέθηκε ότι οι ενώσεις του γενικού τύπου (I) είναι ανταγωνιστές μεταβοτροπικού υποδοχέα γλουταμινικού. Μπορούν να χρησιμοποιηθούν στη θεραπευτική αντιμετώπιση ή την πρόληψη διαταραχών στις οποίες μεσολαβεί υποδοχέας mGluR5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09165780 | 2009-07-17 | ||
| EP10730192.1A EP2456765B1 (en) | 2009-07-17 | 2010-07-14 | Imidazole derivatives as mglur5 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114186T1 true CY1114186T1 (el) | 2016-08-31 |
Family
ID=42358156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100614T CY1114186T1 (el) | 2009-07-17 | 2013-07-22 | Παραγωγα ιμιδαζολιου ως ανταγωνιστες mglur5 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8334287B2 (el) |
| EP (1) | EP2456765B1 (el) |
| JP (1) | JP5667182B2 (el) |
| KR (1) | KR101431347B1 (el) |
| CN (1) | CN102471309B (el) |
| AR (1) | AR077481A1 (el) |
| AU (1) | AU2010272585B2 (el) |
| BR (1) | BR112012001092A2 (el) |
| CA (1) | CA2765921C (el) |
| CL (1) | CL2012000102A1 (el) |
| CO (1) | CO6400142A2 (el) |
| CR (1) | CR20110659A (el) |
| CY (1) | CY1114186T1 (el) |
| DK (1) | DK2456765T3 (el) |
| EC (1) | ECSP12011611A (el) |
| ES (1) | ES2411467T3 (el) |
| HK (1) | HK1169397A1 (el) |
| HR (1) | HRP20130657T1 (el) |
| IL (1) | IL216746A (el) |
| MA (1) | MA33386B1 (el) |
| MX (1) | MX2012000814A (el) |
| MY (1) | MY156878A (el) |
| NZ (1) | NZ596810A (el) |
| PE (1) | PE20120397A1 (el) |
| PL (1) | PL2456765T3 (el) |
| PT (1) | PT2456765E (el) |
| RS (1) | RS52901B (el) |
| RU (1) | RU2527106C2 (el) |
| SG (1) | SG178052A1 (el) |
| SI (1) | SI2456765T1 (el) |
| TW (1) | TWI423964B (el) |
| UA (1) | UA107086C2 (el) |
| WO (1) | WO2011006910A1 (el) |
| ZA (1) | ZA201109451B (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| WO2015143164A1 (en) * | 2014-03-19 | 2015-09-24 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2202840T3 (es) * | 1997-04-24 | 2004-04-01 | Ortho-Mcneil Pharmaceutical, Inc. | Imidazoles sustituidos utiles en el tratamiento de enfermedades inflamatorias. |
| ATE288898T1 (de) | 2000-12-04 | 2005-02-15 | Hoffmann La Roche | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| ES2358512T3 (es) * | 2003-06-12 | 2011-05-11 | F. Hoffmann-La Roche Ag | Derivados de imidazol, sustituidos por heteroarilo como antagonistas del receptor de glutamato. |
| US7452909B2 (en) | 2003-09-04 | 2008-11-18 | Hoffman-La Roche Inc. | Imidazole derivatives |
| EP1756086B1 (en) | 2004-06-01 | 2008-06-04 | F.Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
| BRPI0511678A (pt) * | 2004-06-01 | 2008-01-08 | Hoffmann La Roche | piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5 |
| JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
-
2010
- 2010-07-09 US US12/833,017 patent/US8334287B2/en active Active
- 2010-07-14 KR KR1020127004121A patent/KR101431347B1/ko active IP Right Grant
- 2010-07-14 BR BR112012001092-1A patent/BR112012001092A2/pt not_active Application Discontinuation
- 2010-07-14 CN CN201080031886.6A patent/CN102471309B/zh active Active
- 2010-07-14 RS RS20130331A patent/RS52901B/en unknown
- 2010-07-14 TW TW099123206A patent/TWI423964B/zh not_active IP Right Cessation
- 2010-07-14 JP JP2012520013A patent/JP5667182B2/ja active Active
- 2010-07-14 DK DK10730192.1T patent/DK2456765T3/da active
- 2010-07-14 EP EP10730192.1A patent/EP2456765B1/en active Active
- 2010-07-14 NZ NZ596810A patent/NZ596810A/en not_active IP Right Cessation
- 2010-07-14 MX MX2012000814A patent/MX2012000814A/es active IP Right Grant
- 2010-07-14 ES ES10730192T patent/ES2411467T3/es active Active
- 2010-07-14 SI SI201030209T patent/SI2456765T1/sl unknown
- 2010-07-14 PL PL10730192T patent/PL2456765T3/pl unknown
- 2010-07-14 MA MA34494A patent/MA33386B1/fr unknown
- 2010-07-14 PE PE2012000035A patent/PE20120397A1/es not_active Application Discontinuation
- 2010-07-14 WO PCT/EP2010/060097 patent/WO2011006910A1/en active Application Filing
- 2010-07-14 PT PT107301921T patent/PT2456765E/pt unknown
- 2010-07-14 CA CA2765921A patent/CA2765921C/en not_active Expired - Fee Related
- 2010-07-14 RU RU2012104399/04A patent/RU2527106C2/ru not_active IP Right Cessation
- 2010-07-14 SG SG2012003661A patent/SG178052A1/en unknown
- 2010-07-14 UA UAA201201027A patent/UA107086C2/ru unknown
- 2010-07-14 AU AU2010272585A patent/AU2010272585B2/en not_active Ceased
- 2010-07-14 MY MYPI2012000151A patent/MY156878A/en unknown
- 2010-07-15 AR ARP100102580A patent/AR077481A1/es unknown
-
2011
- 2011-11-29 CO CO11164352A patent/CO6400142A2/es active IP Right Grant
- 2011-12-01 IL IL216746A patent/IL216746A/en not_active IP Right Cessation
- 2011-12-08 CR CR20110659A patent/CR20110659A/es unknown
- 2011-12-21 ZA ZA2011/09451A patent/ZA201109451B/en unknown
-
2012
- 2012-01-13 CL CL2012000102A patent/CL2012000102A1/es unknown
- 2012-01-17 EC EC2012011611A patent/ECSP12011611A/es unknown
- 2012-10-12 HK HK12110080.6A patent/HK1169397A1/xx unknown
-
2013
- 2013-07-10 HR HRP20130657AT patent/HRP20130657T1/hr unknown
- 2013-07-22 CY CY20131100614T patent/CY1114186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110952T1 (el) | Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3 | |
| CY1117638T1 (el) | Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης | |
| WO2006109075A3 (en) | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 | |
| CY1114277T1 (el) | ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ | |
| CY1107244T1 (el) | Μιμητικα γλυκοκορτικοειδων, μεθοδοι παρασκευης τους, φαρμακευτικες συνθεσεις και χρησεις τους | |
| ECSP034640A (es) | Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato | |
| TW200633698A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| MY153719A (en) | Prokineticin 1 receptor antagonists | |
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| CY1119289T1 (el) | Παραγωγα 1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης υποκατεστημενα με ετεροκυκλικους δακτυλιους ως αντι-ιικοι παραγοντες αναπνευστικου συγκυτιακου ιου | |
| MX2010008362A (es) | Derivados de heteroarilamida diazepinopirimidona sustituidos. | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| CY1116391T1 (el) | Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5 | |
| ATE435223T1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| CY1113733T1 (el) | Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων | |
| PE20090629A1 (es) | Pirazinas y piperidinas piperazinil sustituidas como antagonistas del receptor 5-ht7 | |
| CY1114186T1 (el) | Παραγωγα ιμιδαζολιου ως ανταγωνιστες mglur5 | |
| ATE512142T1 (de) | Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität | |
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |